PriceTargets.com logo

Doximity - DOCS Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $40.50
  • Forecasted Upside: 24.58%
  • Number of Analysts: 13
  • Breakdown:
  • 3 Sell Ratings
  • 3 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$32.51 As of 03/24/2023 01:00 AM ET
▼ -0.4 (-1.22%)

This chart shows the closing price for DOCS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Doximity Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DOCS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DOCS

Analyst Price Target is $40.50
▲ +24.58% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Doximity in the last 3 months. The average price target is $40.50, with a high forecast of $56.00 and a low forecast of $29.00. The average price target represents a 24.58% upside from the last price of $32.51.

This chart shows the closing price for DOCS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 13 polled investment analysts is to hold stock in Doximity. This rating has held steady since August 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
10/2/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
12/31/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
3/31/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 3 sell ratings
Ratings as of
6/29/2022
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 3 sell ratings
Ratings as of
9/27/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 2 sell ratings
Ratings as of
12/26/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 3 sell ratings
Ratings as of
2/24/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 3 sell ratings
Ratings as of
3/26/2023

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 3 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/17/2023JPMorgan Chase & Co.Lower TargetUnderweight$60.00 ➝ $30.00Low
2/10/2023Piper SandlerBoost Target$35.00 ➝ $38.00Low
2/10/2023Wells Fargo & CompanyLower TargetOverweight$44.00 ➝ $39.00Low
2/10/2023Canaccord Genuity GroupLower TargetBuy$42.00 ➝ $41.00Low
2/10/2023Needham & Company LLCReiterated RatingBuy$45.00Low
1/6/2023Morgan StanleyDowngradeEqual Weight ➝ Underweight$32.00 ➝ $29.00Low
11/11/2022Evercore ISIBoost Target$28.00 ➝ $32.00Low
11/11/2022Wells Fargo & CompanyBoost TargetOverweight$38.00 ➝ $44.00Low
11/11/2022Piper SandlerLower Target$39.00 ➝ $35.00Low
10/31/2022Wells Fargo & CompanyInitiated CoverageOverweight$38.00Low
10/23/2022Evercore ISIInitiated CoverageInline$28.00Low
10/13/2022BTIG ResearchInitiated CoverageNeutralLow
9/15/2022KeyCorpInitiated CoverageSector Weight ➝ Sector WeightLow
9/7/2022Truist FinancialInitiated CoverageHold$35.00Low
8/8/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$47.00 ➝ $42.00Low
8/5/2022Canaccord Genuity GroupLower TargetBuy$47.00 ➝ $42.00Low
8/5/2022Bank of AmericaDowngradeNeutral ➝ Underperform$43.00 ➝ $29.00Low
8/5/2022Piper SandlerLower Target$44.00 ➝ $39.00Low
7/29/2022Berenberg BankReiterated RatingInitiatesLow
7/28/2022Berenberg BankInitiated CoverageBuy$49.00Low
5/18/2022Piper SandlerLower Target$81.00 ➝ $44.00High
5/18/2022Canaccord Genuity GroupLower Target$65.00 ➝ $44.00High
5/18/2022Jefferies Financial GroupLower TargetBuy$78.00 ➝ $46.00High
5/18/2022Bank of AmericaLower TargetNeutral$55.00 ➝ $36.00High
5/18/2022GuggenheimLower TargetBuy$70.00 ➝ $52.00High
5/18/2022Needham & Company LLCLower TargetBuy$70.00 ➝ $45.00High
5/18/2022The Goldman Sachs GroupLower TargetBuy$72.00 ➝ $56.00High
5/18/2022Morgan StanleyLower TargetEqual Weight$55.00 ➝ $35.00High
5/18/2022Raymond JamesLower Target$60.00 ➝ $40.00High
5/18/2022Robert W. BairdLower Target$68.00 ➝ $45.00High
4/6/2022GuggenheimInitiated CoverageBuy$70.00Low
4/4/2022Bank of AmericaInitiated CoverageNeutral$55.00Low
3/23/2022Morgan StanleyLower TargetEqual Weight$62.00 ➝ $55.00Medium
2/11/2022The Goldman Sachs GroupInitiated CoverageBuy$74.00High
2/9/2022Needham & Company LLCLower TargetBuy$90.00 ➝ $70.00High
2/9/2022Raymond JamesLower TargetOutperform$80.00 ➝ $60.00High
12/17/2021Morgan StanleyLower TargetEqual Weight$72.00 ➝ $58.00Low
12/14/2021JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$70.00 ➝ $60.00Medium
12/1/2021Jefferies Financial GroupInitiated CoverageBuy$78.00High
11/16/2021Robert W. BairdInitiated CoverageOutperform$84.00Low
11/10/2021The Goldman Sachs GroupBoost TargetNeutral$40.00 ➝ $45.00High
11/10/2021Morgan StanleyBoost TargetEqual Weight$71.00 ➝ $72.00High
11/10/2021Raymond JamesBoost TargetOutperform$62.00 ➝ $80.00High
11/10/2021SVB LeerinkBoost TargetOutperform$65.00 ➝ $72.00High
11/10/2021Needham & Company LLCBoost TargetBuy$62.00 ➝ $90.00High
11/10/2021Piper SandlerBoost TargetOverweight$68.00 ➝ $81.00High
8/31/2021Morgan StanleyBoost TargetEqual Weight$52.00 ➝ $71.00High
8/26/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$70.00High
8/11/2021Raymond JamesBoost TargetOutperform$60.00 ➝ $62.00High
7/19/2021Needham & Company LLCInitiated CoverageBuy$62.00High
7/19/2021JPMorgan Chase & Co.Initiated CoverageOverweight$60.00High
7/19/2021Raymond JamesInitiated CoverageOutperform$60.00High
7/19/2021Morgan StanleyInitiated CoverageEqual Weight$52.00High
7/19/2021William BlairInitiated CoverageOutperformHigh
7/19/2021SVB LeerinkInitiated CoverageOutperform$65.00High
7/19/2021The Goldman Sachs GroupInitiated CoverageNeutralHigh
7/19/2021Piper SandlerInitiated CoverageOverweight$68.00High
(Data available from 3/26/2018 forward)

News Sentiment Rating

0.73 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
8/28/2022
  • 6 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2022
  • 4 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2022
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2022
  • 3 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2023
  • 13 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2023
  • 9 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
3/26/2023

Current Sentiment

  • 9 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Doximity logo
Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical manufacturers and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $32.51
Low: $32.22
High: $33.05

50 Day Range

MA: $33.49
Low: $29.08
High: $39.66

52 Week Range

Now: $32.51
Low: $22.91
High: $54.69

Volume

1,297,654 shs

Average Volume

1,480,727 shs

Market Capitalization

$6.29 billion

P/E Ratio

59.11

Dividend Yield

N/A

Beta

0.87

Frequently Asked Questions

What sell-side analysts currently cover shares of Doximity?

The following sell-side analysts have issued reports on Doximity in the last twelve months: Bank of America Co., Berenberg Bank, BTIG Research, Canaccord Genuity Group Inc., Evercore ISI, Guggenheim, Jefferies Financial Group Inc., JPMorgan Chase & Co., KeyCorp, Morgan Stanley, Needham & Company LLC, Piper Sandler, Raymond James, Robert W. Baird, The Goldman Sachs Group, Inc., Truist Financial Co., and Wells Fargo & Company.
View the latest analyst ratings for DOCS.

What is the current price target for Doximity?

16 Wall Street analysts have set twelve-month price targets for Doximity in the last year. Their average twelve-month price target is $40.50, suggesting a possible upside of 24.6%. The Goldman Sachs Group, Inc. has the highest price target set, predicting DOCS will reach $56.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $29.00 for Doximity in the next year.
View the latest price targets for DOCS.

What is the current consensus analyst rating for Doximity?

Doximity currently has 3 sell ratings, 3 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in DOCS, but not buy more shares or sell existing shares.
View the latest ratings for DOCS.

What other companies compete with Doximity?

Other companies that are similar to Doximity include Acadia Healthcare, Envista, Natera, Ascendis Pharma A/S and NovoCure. Learn More about companies similar to Doximity.

How do I contact Doximity's investor relations team?

The company's listed phone number is 650-549-4330 and its investor relations email address is [email protected] The official website for Doximity is www.doximity.com. Learn More about contacing Doximity investor relations.